PRME
Prime Medicine
No price yet
Announcements
Nothing here yet
Daily updates
- Prime Medicine initiated patient dosing in its global Phase 1/2 study of PM577a for H1069Q-mutated Wilson disease, marking its first clinical in vivo Prime Editing program.Oct 7, 2026
- Prime Medicine initiated patient dosing in a global Phase 1/2 trial of PM577a for Wilson disease with the H1069Q mutation, marking the first clinical administration of its in vivo Prime Editing technology.Oct 6, 2026
- Prime Medicine secured FDA IND clearance for PM647 for alpha-1 antitrypsin deficiency, enabling domestic clinical trials and advancing its in vivo prime-editing pipeline.Sep 25, 2026
FDA designations
Nothing here yet
News
- Prime Medicine receives U.S. FDA clearance of the IND application for PM647 in alpha-1 antitrypsin deficiencySep 25, 2026
- Prime Medicine receives FDA clearance of IND application for PM577a in H1069Q-mutated Wilson diseaseJul 24, 2026
- Prime Medicine received FDA RMAT designation for PM359 in chronic granulomatous diseaseJun 22, 2026
- Prime Medicine received New Zealand clearance for a clinical trial application of PM577a in H1069Q-mutated Wilson diseaseJun 18, 2026
- Prime Medicine announces breakthrough clinical data showing rapid restoration of DHR positivity after a single infusion of PM359, an investigational prime editor for chronic granulomatous disease.May 19, 2025